Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, ureter cancer, ureteral disorder, urethra neoplasm, urethral disorder, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma	Active, not recruiting	Phase 2	2021-11-04		NCT03179943

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fox Chase Cancer Center	58
Stand Up To Cancer	20
Van Andel Research Institute	7

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fox Chase Cancer Center	Philadelphia	United States	259
Johns Hopkins University School of Medicine	Baltimore	United States	36
USC Norris Hospital and Clinics	Los Angeles	United States	1